Aleksas Matvekas

Strategies toward Discovery of Potent and Orally Bioavailable Proteolysis Targeting Chimera Degraders of Androgen Receptor for the Treatment of Prostate Cancer.

Shaomeng Wang, D. McEachern, B. Miao, 2021, Journal of medicinal chemistry.

Discovery of ARD-2585 as an Exceptionally Potent and Orally Active PROTAC Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

Shaomeng Wang, D. McEachern, B. Miao, 2021, Journal of medicinal chemistry.

Probing the interaction between the histone methyltransferase/deacetylase subunit RBBP4/7 and the transcription factor BCL11A in epigenetic complexes

Inkyung Jung, J. Stuckey, J. Meagher, 2017, The Journal of Biological Chemistry.

Alteration in Acute Kidney Injury Potential with the Combination of Vancomycin and Imipenem-Cilastatin/Relebactam or Piperacillin/Tazobactam in a Preclinical Model

Miao He, M. Pai, R. L. Crass, 2021, Antimicrobial Agents and Chemotherapy.

Panobinostat penetrates the blood–brain barrier and achieves effective brain concentrations in a murine model

B. Marini, C. Koschmann, Miao He, 2021, Cancer Chemotherapy and Pharmacology.

Discovery of ARD-2051 as a Potent and Orally Efficacious Proteolysis Targeting Chimera (PROTAC) Degrader of Androgen Receptor for the Treatment of Advanced Prostate Cancer.

D. McEachern, B. Miao, Mi Wang, 2023, Journal of medicinal chemistry.